- Home
- RILYP vs VCEL Comparison
RILYP vs VCEL Comparison
Compare RILYP & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RILYP
- VCEL
- Stock Information
- Founded
- RILYP 1973
- VCEL 1989
- Country
- RILYP United States
- VCEL United States
- Employees
- RILYP 2056
- VCEL N/A
- Industry
- RILYP Investment Managers
- VCEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RILYP Finance
- VCEL Health Care
- Exchange
- RILYP Nasdaq
- VCEL Nasdaq
- Market Cap
- RILYP N/A
- VCEL 1.6B
- IPO Year
- RILYP N/A
- VCEL 1997
- Fundamental
- Price
- RILYP $5.76
- VCEL $36.03
- Analyst Decision
- RILYP
- VCEL Strong Buy
- Analyst Count
- RILYP 0
- VCEL 6
- Target Price
- RILYP N/A
- VCEL $58.60
- AVG Volume (30 Days)
- RILYP 38.1K
- VCEL 629.6K
- Earning Date
- RILYP 01-01-0001
- VCEL 11-06-2025
- Dividend Yield
- RILYP 7.03%
- VCEL N/A
- EPS Growth
- RILYP N/A
- VCEL 2045.40
- EPS
- RILYP N/A
- VCEL 0.13
- Revenue
- RILYP $854,383,000.00
- VCEL $249,119,000.00
- Revenue This Year
- RILYP N/A
- VCEL $18.35
- Revenue Next Year
- RILYP N/A
- VCEL $22.26
- P/E Ratio
- RILYP N/A
- VCEL $270.38
- Revenue Growth
- RILYP N/A
- VCEL 16.13
- 52 Week Low
- RILYP $1.73
- VCEL $29.24
- 52 Week High
- RILYP $20.00
- VCEL $63.00
- Technical
- Relative Strength Index (RSI)
- RILYP 45.64
- VCEL 59.82
- Support Level
- RILYP $5.44
- VCEL $33.14
- Resistance Level
- RILYP $5.93
- VCEL $36.87
- Average True Range (ATR)
- RILYP 0.39
- VCEL 1.54
- MACD
- RILYP -0.03
- VCEL 0.51
- Stochastic Oscillator
- RILYP 38.01
- VCEL 87.00
About RILYP B. Riley Financial Inc.
B. Riley Financial Inc is a diversified financial services company. The company through its subsidiaries offers investment banking and financial services to corporate, institutional, and high-net-worth clients and also asset disposition, valuation and appraisal, and capital advisory services to retail, wholesale, institutional, lenders, capital providers, private equity investors, and professional services firms in United States, Canada, and Europe. It also provides internet access and subscription services. The reportable operating segments of the company include Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications segment, and Consumer products segment.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.